Oppenheimer Maintains an 'Outperform' on Immunogen Inc. (IMGN); Advancing NORTH
Tweet
Share
E-mailGet Alerts IMGN Hot Sheet
Price: $31.25 --0%
Rating Summary:
5 Buy, 17 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
5 Buy, 17 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Oppenheimer maintains an 'Outperform' on Immunogen Inc. (NASDAQ: IMGN) price target of $18.00.
Analyst, Boris Peaker, said, "ImmunoGen presented data from its Phase I dose-finding trial of IMGN901. This dosing is being used in the Phase II (NORTH) trial in first-line small-cell lung cancer (SCLC). The assessment demonstrated that IMGN901 can be administered in combination with a etoposide/carboplatin (E/C) regimen at full single-agent dose. This is is the basis for the dosing in the NORTH study. Specifically, the IMGN901 dose tested in NORTH is 112mg/m2 with carboplatin AUC5 and etoposide at 100mg/m2 given on days 1-3 every 21 days. The most common grade 1-2 adverse event in Phase I was peripheral neuropathy, and the most common grade 3-4 AE was myelosuppression (associated previously with C/E)."
FY12 EPS estimate raised from (0.97) to (0.95), but FY13 lowered from (0.72) to (0.89)
For an analyst ratings summary and ratings history on Immunogen Inc. click here. For more ratings news on Immunogen Inc. click here.
Shares of Immunogen Inc. closed at $14.92 yesterday.
Analyst, Boris Peaker, said, "ImmunoGen presented data from its Phase I dose-finding trial of IMGN901. This dosing is being used in the Phase II (NORTH) trial in first-line small-cell lung cancer (SCLC). The assessment demonstrated that IMGN901 can be administered in combination with a etoposide/carboplatin (E/C) regimen at full single-agent dose. This is is the basis for the dosing in the NORTH study. Specifically, the IMGN901 dose tested in NORTH is 112mg/m2 with carboplatin AUC5 and etoposide at 100mg/m2 given on days 1-3 every 21 days. The most common grade 1-2 adverse event in Phase I was peripheral neuropathy, and the most common grade 3-4 AE was myelosuppression (associated previously with C/E)."
FY12 EPS estimate raised from (0.97) to (0.95), but FY13 lowered from (0.72) to (0.89)
For an analyst ratings summary and ratings history on Immunogen Inc. click here. For more ratings news on Immunogen Inc. click here.
Shares of Immunogen Inc. closed at $14.92 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
- Freedom Broker Upgrades Serve Robotics (SERV) to Buy
- Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS ViewSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
